Concord Biotech Limited (NSE:CONCORDBIO)

Concord Biotech Statistics

Total Valuation

Concord Biotech has a market cap or net worth of INR 119.85 billion. The enterprise value is 116.54 billion.

Market Cap	119.85B
Enterprise Value	116.54B

Important Dates

The last earnings date was Wednesday, February 11, 2026.

Earnings Date	Feb 11, 2026
Ex-Dividend Date	Sep 3, 2025

Share Statistics

Concord Biotech has 104.62 million shares outstanding. The number of shares has increased by 0.63% in one year.

Current Share Class	104.62M
Shares Outstanding	104.62M
Shares Change (YoY)	+0.63%
Shares Change (QoQ)	+0.57%
Owned by Insiders (%)	60.90%
Owned by Institutions (%)	15.11%
Float	26.59M

Valuation Ratios

The trailing PE ratio is 38.59 and the forward PE ratio is 29.92. Concord Biotech's PEG ratio is 2.10.

PE Ratio	38.59
Forward PE	29.92
PS Ratio	10.34
PB Ratio	6.56
P/TBV Ratio	6.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	2.10

Enterprise Valuation

EV / Earnings	37.29
EV / Sales	10.06
EV / EBITDA	26.83
EV / EBIT	30.71
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.00
Debt / EBITDA	0.00
Debt / FCF	n/a
Interest Coverage	1,282.33

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	18.97%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	5.47%
Revenue Per Employee	7.38M
Profits Per Employee	1.99M
Employee Count	1,571
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Concord Biotech has paid 1.03 billion in taxes.

Income Tax	1.03B
Effective Tax Rate	24.86%

Stock Price Statistics

The stock price has decreased by -31.79% in the last 52 weeks. The beta is 0.22, so Concord Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.22
52-Week Price Change	-31.79%
50-Day Moving Average	1,285.09
200-Day Moving Average	1,561.04
Relative Strength Index (RSI)	38.70
Average Volume (20 Days)	318,468

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Concord Biotech had revenue of INR 11.59 billion and earned 3.13 billion in profits. Earnings per share was 29.69.

Revenue	11.59B
Gross Profit	7.41B
Operating Income	3.78B
Pretax Income	4.14B
Net Income	3.13B
EBITDA	4.31B
EBIT	3.78B
Earnings Per Share (EPS)	29.69

Balance Sheet

The company has 3.31 billion in cash and 16.07 million in debt, with a net cash position of 3.30 billion or 31.52 per share.

Cash & Cash Equivalents	3.31B
Total Debt	16.07M
Net Cash	3.30B
Net Cash Per Share	31.52
Equity (Book Value)	18.27B
Book Value Per Share	173.32
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 63.92%, with operating and profit margins of 32.61% and 26.97%.

Gross Margin	63.92%
Operating Margin	32.61%
Pretax Margin	35.74%
Profit Margin	26.97%
EBITDA Margin	37.20%
EBIT Margin	32.61%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 10.70, which amounts to a dividend yield of 0.92%.

Dividend Per Share	10.70
Dividend Yield	0.92%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	2
Payout Ratio	n/a
Buyback Yield	-0.63%
Shareholder Yield	0.29%
Earnings Yield	2.61%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1